Solara Active Pharma Sciences Limited — Important, 24-01-2025: General Updates

The Board of Directors of Solara Active Pharma Sciences Limited has approved the unaudited financial results for the quarter and nine months ended December 31, 2024. The results reveal key financial metrics that were positively impacted, and the figures will be available on the company’s website for reference.

Additionally, the Board has granted in-principle approval to explore a potential demerger of the CRAMS and Polymers business into an independent listed entity. This strategic move aims to enhance focus on these businesses and is expected to facilitate better growth and differentiation in their operations. Management is now tasked with taking necessary preparatory steps, including appointing valuers and drafting a scheme of arrangement for further evaluation by the Board. The outlook for investors could be positive, contingent on the success of these initiatives. Investors should watch this space closely for developments.